BOSTON–a2z Radiology AI Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a2z-Omni-Triage, its third AI-powered medical imaging device designed to identify potentially urgent findings in abdominal and pelvic CT scans.
The latest clearance expands the company’s portfolio to 26 findings across three FDA-cleared devices, strengthening its capabilities in automated triage and notification for acute care imaging.
The newly cleared a2z-Omni-Triage system is designed to flag suspected cases of nine medical conditions, including moderate or large pleural effusion, pneumothorax, complex pleural collection, bowel perforation, moderate or severe hydronephrosis, large aortic aneurysms measuring at least five centimeters, non-sacral pelvic fractures, sacral or coccygeal fractures, and soft tissue abscesses.
The device joins a2z-Unified-Triage, which is cleared to identify seven findings, and a2z-Abdo-Triage, which covers ten findings. Each device underwent separate performance testing and received FDA clearance based on its specific clinical indications.
“A CT scan ordered for abdominal pain shows far more than the abdomen, from the base of the lungs to the bones of the pelvis,” said Samir Rajpurkar, Co-Founder and CEO of a2z Radiology AI. “a2z-Omni-Triage can flag nine findings across that range for the care team.”
The technology is intended to help radiologists and other healthcare professionals identify scans that may require urgent review, particularly in clinical environments where imaging workloads are high.
“On a busy shift with a long worklist, even a CT ordered as routine can turn out to need urgent attention,” said Michael Moritz, MD, CIIP, Chief Medical Information Officer of a2z Radiology AI. “a2z-Omni-Triage helps bring those studies with suspected findings forward for review.”
Unlike AI imaging tools focused on individual conditions, a2z’s expanding portfolio is designed to evaluate multiple potential abnormalities within the same CT examination.
“A scan isn’t read one finding at a time, and the software that supports clinicians shouldn’t stop at one either,” said Pranav Rajpurkar, PhD, Co-Founder of a2z Radiology AI and Associate Professor of Biomedical Informatics at Harvard Medical School.
The a2z-Omni-Triage system analyzes abdominal and pelvic CT images acquired with or without intravenous contrast in patients aged 22 and older. It operates alongside standard clinical image interpretation and provides notifications when potentially urgent findings are detected.
The company emphasized that the technology is intended to support clinical decision-making rather than replace radiologists. Healthcare professionals remain responsible for reviewing complete imaging studies and making diagnostic determinations.
For findings involving the chest, the system’s analysis is limited to cases where the relevant anatomy is captured within the abdominal or pelvic CT images.
The latest FDA clearance marks another regulatory milestone for a2z Radiology AI as it expands its AI-based imaging tools for acute care settings.


